Sustained response to low‐dose rituximab in idiopathic autoimmune hemolytic anemia

To evaluate the sustained response to low‐dose (LD) rituximab in autoimmune hemolytic anemia (AIHA), the ex vivo effect on anti‐RBC antibody production by mitogen‐stimulated direct antiglobulin test (MS‐DAT), and the in vitro dose effect of the drug on the production of anti‐RBC antibodies.

[1]  Michelle A. Mathiason,et al.  Outcomes and complications after splenectomy for hematologic disorders. , 2012, American journal of surgery.

[2]  R. Fanin,et al.  Long‐term follow‐up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia , 2012, American journal of hematology.

[3]  Caroline Gordon,et al.  Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis , 2012, Annals of the rheumatic diseases.

[4]  E. Neufeld,et al.  Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. , 2012, Blood.

[5]  R. Fanin,et al.  Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studies. , 2012, Blood.

[6]  R. Stasi.  Immune Thrombocytopenia: Pathophysiologic and Clinical Update , 2012, Seminars in Thrombosis & Hemostasis.

[7]  Yujuan Gao,et al.  Efficacy of Low-Dose Rituximab in a Refractory Acquired Factor VIII Inhibitor Case Secondary to Pemphigus , 2011, Acta Haematologica.

[8]  A. Zanella,et al.  Rituximab therapy for autoimmune haematological diseases. , 2011, European journal of internal medicine.

[9]  S. Berentsen.  How I manage cold agglutinin disease , 2011, British journal of haematology.

[10]  Masao Kobayashi,et al.  [Sustained complete remission for one year following low-dose rituximab therapy for chronic autoimmune neutropenia]. , 2011, [Rinsho ketsueki] The Japanese journal of clinical hematology.

[11]  P. Mccombe,et al.  Use and monitoring of low dose rituximab in myasthenia gravis , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[12]  R. Fanin,et al.  Low‐dose rituximab in adult patients with primary immune thrombocytopenia , 2010, European journal of haematology.

[13]  U. Jäger,et al.  How I treat autoimmune hemolytic anemias in adults. , 2010, Blood.

[14]  M. Fernández-Aceñero,et al.  Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolytic anemia , 2010, Annals of Hematology.

[15]  Drew Provan,et al.  International consensus report on the investigation and management of primary immune thrombocytopenia. , 2010, Blood.

[16]  Stanley B. Cohen,et al.  Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. , 2006, Arthritis and rheumatism.

[17]  L. Kjeldsen,et al.  Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients , 2006, Leukemia & lymphoma.

[18]  L. Arcaini,et al.  Pharmacokinetic Behavior of Rituximab: A Study of Different Schedules of Administration for Heterogeneous Clinical Settings , 2005, Therapeutic drug monitoring.

[19]  S. Vesely,et al.  Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. , 2004, Blood.

[20]  E. Targarona,et al.  Long-term outcome after laparoscopic splenectomy related to hematologic diagnosis , 2004, Surgical Endoscopy And Other Interventional Techniques.

[21]  A. Zanella,et al.  In vitro quantification of anti‐red blood cell antibody production in idiopathic autoimmune haemolytic anaemia: effect of mitogen and cytokine stimulation , 2000, British journal of haematology.

[22]  J. George,et al.  Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. , 1996, Blood.

[23]  J. Bussel,et al.  Avoiding intuxication. , 2012, Blood.

[24]  St Michael’s.  Rituximab in the treatment of autoimmune haematological disorders , 2008 .

[25]  T. Barbui,et al.  Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases. , 2005, Haematologica.